• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    8/23/23 1:31:09 PM ET
    $ADTX
    $APLS
    $AXLA
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email

    Gainers

    • Apellis Pharmaceuticals (NASDAQ:APLS) shares rose 30.2% to $40.05 during Wednesday's regular session. Trading volume for Apellis Pharmaceuticals's stock is 9.9 million as of 13:31 EST. This is 229.8% of its average full-day volume over the last 100 days. The company's market cap stands at $4.7 billion.
    • Aditxt (NASDAQ:ADTX) stock increased by 29.82% to $12.99. Trading volume for Aditxt's stock is 441.2K as of 13:31 EST. This is 745.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.4 million.
    • ITeos Therapeutics (NASDAQ:ITOS) shares moved upwards by 26.63% to $14.88. Trading volume for ITeos Therapeutics's stock is 8.2 million as of 13:31 EST. This is 2903.5% of its average full-day volume over the last 100 days. The company's market cap stands at $532.4 million.
    • RVL Pharmaceuticals (NASDAQ:RVLP) shares increased by 26.35% to $0.18. As of 13:31 EST, this security is trading at a volume of 5.4 million shares, making up 2155.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.6 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) shares increased by 22.49% to $3.54. Bullfrog AI Hldgs's stock is trading at a volume of 775.5K shares as of 13:31 EST. This is 63.8% of its average full-day volume over the last 100 days. The company's market cap stands at $21.5 million.
    • Arcus Biosciences (NYSE:RCUS) shares increased by 21.5% to $22.86. Arcus Biosciences's stock is trading at a volume of 3.3 million shares as of 13:31 EST. This is 330.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.7 billion.

    Losers

    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) stock fell 33.3% to $0.05 during Wednesday's regular session. Longeveron Inc. - Subscription Right's stock is trading at a volume of 129.6K shares as of 13:31 EST. This is 528.8% of its average full-day volume over the last 100 days.
    • GRI Bio (NASDAQ:GRI) stock declined by 23.14% to $2.06. Trading volume for GRI Bio's stock is 2.1 million as of 13:31 EST. This is 18550.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.0 million.
    • Mallinckrodt (AMEX:MNK) shares declined by 20.94% to $0.46. Trading volume for this security as of 13:31 EST is 1.4 million, which is 39.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.1 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) shares fell 16.72% to $0.57. Trading volume for this security as of 13:31 EST is 225.2K, which is 188.5% of its average full-day volume over the last 100 days. The company's market cap stands at $9.7 million.
    • Axcella Health (NASDAQ:AXLA) shares declined by 16.67% to $0.14. The current volume of 3.0 million shares is 282.9% of Axcella Health's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $10.6 million.
    • Jin Medical International (NASDAQ:ZJYL) stock fell 15.89% to $11.44. The current volume of 291.5K shares is 145.0% of Jin Medical International's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $88.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $APLS
    $AXLA
    $BFRG

    CompanyDatePrice TargetRatingAnalyst
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    Arcus Biosciences Inc.
    $RCUS
    2/12/2026$23.00Overweight → Equal Weight
    Wells Fargo
    Apellis Pharmaceuticals Inc.
    $APLS
    1/28/2026$24.00Equal Weight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    1/21/2026$28.00Neutral → Buy
    BofA Securities
    Arcus Biosciences Inc.
    $RCUS
    1/13/2026$28.00Neutral → Buy
    Goldman
    Arcus Biosciences Inc.
    $RCUS
    1/8/2026$20.00Overweight → Equal-Weight
    Morgan Stanley
    Apellis Pharmaceuticals Inc.
    $APLS
    11/6/2025Peer Perform
    Wolfe Research
    Apellis Pharmaceuticals Inc.
    $APLS
    10/15/2025$32.00Overweight
    Wells Fargo
    More analyst ratings

    $ADTX
    $APLS
    $AXLA
    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

    Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis' commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis' talent and expertise will accelerate Biogen's entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3Acquisition is expected to bolster Biogen's near-and long-term growth prospects, adding immediate revenue from two products with significant growth potential; 2025 n

    3/31/26 6:59:00 AM ET
    $APLS
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder

    Commercial agreement serves as high-profile third party validation of BullFrog AI's proprietary capabilities Agreement utilizes BullFrog AI's end-to-end analytical AI platform to accelerate drug discovery and development program  GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue ("Customer"), to apply the Company's proprietary bfLEAP® platform to identify and prioritize

    3/30/26 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine

    GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today unveiled bfARENAS™, a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design, bolstering its end-to-end AI intelligence workflow. The Company will host a webinar in partnership with Xtalks Life Sciences on bfARENAS™ on March 27, 2026 at 11 a.m. ET. Organizations across biotech, pharma, and clinical research operate in high-uncertainty environments where timelines are lon

    3/25/26 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $APLS
    $AXLA
    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Francois Cedric gifted 64,869 shares and received a gift of 64,869 shares, decreasing direct ownership by 13% to 425,968 units (SEC Form 4)

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    3/13/26 4:02:04 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dolsten Mikael was granted 14,312 shares (SEC Form 4)

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    3/3/26 4:06:32 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dolsten Mikael

    3 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    3/3/26 4:05:37 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $APLS
    $AXLA
    $BFRG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

    Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

    5/17/21 11:09:40 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $APLS
    $AXLA
    $BFRG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ecor1 Capital, Llc bought $38,685,562 worth of shares (4,958,978 units at $7.80) (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    5/16/25 6:52:07 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:06:05 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:05:56 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $APLS
    $AXLA
    $BFRG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Apellis Pharmaceuticals with a new price target

    Roth Capital initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $31.00

    3/13/26 8:46:55 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Arcus Biosciences from Overweight to Equal Weight and set a new price target of $23.00

    2/12/26 7:22:07 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Apellis Pharmaceuticals with a new price target

    Barclays initiated coverage of Apellis Pharmaceuticals with a rating of Equal Weight and set a new price target of $24.00

    1/28/26 7:15:29 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $APLS
    $AXLA
    $BFRG
    SEC Filings

    View All

    SEC Form SC TO-C filed by Apellis Pharmaceuticals Inc.

    SC TO-C - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    4/3/26 5:10:30 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Aditxt Inc.

    DEF 14A - Aditxt, Inc. (0001726711) (Filer)

    4/3/26 4:37:32 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Inc. filed SEC Form 8-K: Other Events

    8-K - Aditxt, Inc. (0001726711) (Filer)

    4/2/26 9:13:36 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $APLS
    $AXLA
    $BFRG
    Financials

    Live finance-specific insights

    View All

    Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

    Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis' commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis' talent and expertise will accelerate Biogen's entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3Acquisition is expected to bolster Biogen's near-and long-term growth prospects, adding immediate revenue from two products with significant growth potential; 2025 n

    3/31/26 6:59:00 AM ET
    $APLS
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

    Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing Phase 3 PEAK-1 study, Arcus plans to initiate a Phase 3 study in the first-line (1L) metastatic setting evaluating casdatifan in a tyrosine kinase inhibitor (TKI)-free combination by the end of 2026 With $1.0 billion in cash, cash equivalents and marketable securities at year-

    2/25/26 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $APLS
    $AXLA
    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.  "We are thrilled to welcome Mikael to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Mikael is a proven industry leader with deep experience developing innovative medicine

    3/2/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    $ADTX
    $APLS
    $AXLA
    $BFRG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care